drugset / Trial / NCT02247375

Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

NCT02247375

Phase 1 Completed 26 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety, pharmacokinetics, pharmacodynamics \[CD11b/CD18 (Mac-1) expression\] and efficacy.

Timeline

Start
2000-01
Primary completion
2000-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule 25 mg Oral
Subject AMELUBANT Small molecule 150 mg Oral

Indications